Stifel Stays Sidelined on Acadia Pharma (ACAD) Despite Removal of 'Worst Case Scenario'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 20.70 +0.13 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.57 | 52 Week High | $42.49 | |||
| Open | $21.18 | 52 Week Low | $16.64 | |||
| Day High | $21.29 | P/E | N/A | |||
| Day Low | $20.70 | EPS | $-0.42 | |||
| Volume | 261,349 | |||||
